CymaBay Therapeutics 대차 대조표 상태

재무 상태 기준 확인 4/6

CymaBay Therapeutics 의 총 주주 지분은 $292.3M 이고 총 부채는 $109.2M, 이는 부채 대 자기자본 비율을 37.4% 로 가져옵니다. 총자산과 총부채는 각각 $434.7M 및 $142.4M 입니다.

주요 정보

37.4%

부채 비율

US$109.17m

부채

이자 보상 비율	n/a
현금	US$394.26m
주식	US$292.26m
총 부채	US$142.43m
총 자산	US$434.69m

최근 재무 상태 업데이트

Recent updates

CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Analysts Just Slashed Next Year's Revenue Estimates By 17%

Feb 15

Analysts' Revenue Estimates For CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Are Surging Higher

Dec 22

CymaBay Therapeutics (NASDAQ:CBAY) Has Debt But No Earnings; Should You Worry?

Dec 28

CymaBay Therapeutics GAAP EPS of -$0.31 misses by $0.01

Aug 11

Is CymaBay Therapeutics (NASDAQ:CBAY) Weighed On By Its Debt Load?

Jul 13

CymaBay: Long-Term Potential Based On Prior PBC Trial Results

Jun 27

Is CymaBay Therapeutics (NASDAQ:CBAY) Using Debt In A Risky Way?

Mar 17

Why I've Taken A 'Starter' Position In CymaBay Therapeutics

Jan 20

Is CymaBay Therapeutics (NASDAQ:CBAY) Weighed On By Its Debt Load?

Dec 03

We Think CymaBay Therapeutics (NASDAQ:CBAY) Can Afford To Drive Business Growth

May 15

We're Hopeful That CymaBay Therapeutics (NASDAQ:CBAY) Will Use Its Cash Wisely

Jan 29

CymaBay Therapeutics (CBAY) Presents At AASLD 2020 Conference- Slideshow

Nov 17

CymaBay Is Clawing Back, Now We Just Need Pipeline Conversion

Nov 08

CymaBay Therapeutics EPS in-line

Nov 05

재무 상태 분석

단기부채: CBAY 의 단기 자산 ( $403.8M )이 단기 부채( $36.8M ).

장기 부채: CBAY 의 단기 자산( $403.8M )이 장기 부채( $105.6M ).

부채 대 자본 내역 및 분석

부채 수준: CBAY 총 부채보다 더 많은 현금을 보유하고 있습니다.

부채 감소: CBAY 의 부채 대 자기자본 비율은 지난 5년간 0% 에서 37.4% 로 증가했습니다.

대차 대조표

현금 런웨이 분석

과거에 평균적으로 적자를 기록했던 기업의 경우, 최소 1년 이상의 현금 유동성을 보유하고 있는지 평가합니다.

안정적인 현금 활주로: CBAY 현재 무료 현금 흐름을 기준으로 3년 이상 충분한 현금 활주로를 보유하고 있습니다.

예측 현금 활주로: CBAY 의 여유 현금 흐름이 역사적 비율에 따라 계속 증가하거나 감소하는 경우 충분한 현금 활주로가 있는지 판단하기에는 데이터가 부족합니다.

CymaBay Therapeutics 대차 대조표 상태

재무 상태 기준 확인 4/6

주요 정보

최근 재무 상태 업데이트

CymaBay Therapeutics Files Form 15

CymaBay Therapeutics (NASDAQ:CBAY) Has Debt But No Earnings; Should You Worry?

Is CymaBay Therapeutics (NASDAQ:CBAY) Weighed On By Its Debt Load?

Is CymaBay Therapeutics (NASDAQ:CBAY) Using Debt In A Risky Way?

Is CymaBay Therapeutics (NASDAQ:CBAY) Weighed On By Its Debt Load?

We Think CymaBay Therapeutics (NASDAQ:CBAY) Can Afford To Drive Business Growth

Recent updates

CymaBay Therapeutics Files Form 15

Gilead Sciences, Inc. (NasdaqGS:GILD) completed the acquisition of CymaBay Therapeutics, Inc. (NasdaqGS:CBAY).

President exercised options to buy US$4.5m worth of stock.

CymaBay Therapeutics, Inc. Announces European Medicines Agency Accepts for Review the Marketing Authorization Application for Seladelpar for the Treatment of Primary Biliary Cholangitis

No longer forecast to breakeven

CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Analysts Just Slashed Next Year's Revenue Estimates By 17%

Price target increased by 8.5% to US$31.07

CymaBay Announces FDA Acceptance of NDA and Priority Review for Seladelpar for the Treatment of Primary Biliary Cholangitis

CymaBay Therapeutics, Inc. Announces Executive Changes

Forecast to breakeven in 2026

Analysts' Revenue Estimates For CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Are Surging Higher

Cymabay Therapeutics, Inc. and Lewis Stuart, Chief Commercial Officer, Mutually Agrees on Cease to Be an Officer and Employee Effective December 29, 2023

Cymabay Therapeutics, Inc. Submits New Drug Application to FDA for Seladelpar for the Treatment of Primary Biliary Cholangitis

President exercised options and sold US$973k worth of stock

President notifies of intention to sell stock

Price target increased by 7.5% to US$24.82

New minor risk - Profitability

CymaBay Therapeutics, Inc. Announces Publication of Two-Year Safety and Efficacy Results of Seladelpar in Patients with Primary Biliary Cholangitis

CymaBay Therapeutics, Inc. to Report Q3, 2023 Results on Nov 07, 2023

President exercised options and sold US$597k worth of stock

General Counsel notifies of intention to sell stock

CymaBay Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $224.999939 million.

Price target increased by 17% to US$21.27

Insider notifies of intention to sell stock

Consensus revenue estimates increase by 156%

Price target increased by 8.0% to US$17.64

New minor risk - Profitability

CymaBay Therapeutics, Inc. to Report Q2, 2023 Results on Aug 10, 2023

Consensus revenue estimates fall by 15%

Price target increased by 8.5% to US$15.56

Insider notifies of intention to sell stock

Price target increased by 8.2% to US$14.67

New minor risk - Share price stability

Insider notifies of intention to sell stock

General Counsel notifies of intention to sell stock

Consensus revenue estimates fall by 40%

CymaBay Therapeutics, Inc. to Report Q1, 2023 Results on May 15, 2023

CymaBay Therapeutics, Inc. Appoints Harish Shantharam as Chief Financial Officer

Executive Officer notifies of intention to sell stock

Consensus revenue estimates increase by 24%

Price target increased by 11% to US$13.56

Price target increased by 8.1% to US$11.63

CymaBay Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $84.999785 million.

CymaBay Therapeutics (NASDAQ:CBAY) Has Debt But No Earnings; Should You Worry?

CymaBay Therapeutics Presents Additional Analyses from Clinical Studies of Seladelpar for Patients with Primary Biliary Cholangitis

CymaBay Therapeutics, Inc. Announces Executive Changes

CymaBay Therapeutics GAAP EPS of -$0.31 misses by $0.01

CymaBay Therapeutics, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Cymabay Completes Enrollment for the Response Global Phase 3 Study Evaluating Seladelpar for Patients with Primary Biliary Cholangitis

Is CymaBay Therapeutics (NASDAQ:CBAY) Weighed On By Its Debt Load?

CymaBay: Long-Term Potential Based On Prior PBC Trial Results

CymaBay Therapeutics, Inc.(NasdaqGS:CBAY) dropped from Russell 2000 Dynamic Index

CymaBay Therapeutics, Inc. Presents Positive PBC Data at the International Liver Congress 2022

President recently bought US$100k worth of stock

CymaBay Therapeutics, Inc. Presents New Findings That Seladelpar Treatment of PBC Patients for Two Years Predicts Improved Transplant-Free Survival

Price target decreased to US$10.50

Insufficient new directors

CymaBay Therapeutics, Inc. Appoints Éric Lefebvre to the Audit Committee and the Nominating and Corporate Governance Committee of the Board

Is CymaBay Therapeutics (NASDAQ:CBAY) Using Debt In A Risky Way?

Chief Medical Officer recently bought US$61k worth of stock

Why I've Taken A 'Starter' Position In CymaBay Therapeutics

Is CymaBay Therapeutics (NASDAQ:CBAY) Weighed On By Its Debt Load?

Cymabay Therapeutics, Inc. Announces Positive Data from Its Previously Completed Phase 2 Study and the Enhance Phase 3 Study of Seladelpar in Patients with Primary Biliary Cholangitis

We Think CymaBay Therapeutics (NASDAQ:CBAY) Can Afford To Drive Business Growth

Independent Director has left the company

Price target decreased to US$12.00

CymaBay Therapeutics, Inc. to Report Q4, 2020 Results on Mar 25, 2021

New 90-day low: US$5.32

We're Hopeful That CymaBay Therapeutics (NASDAQ:CBAY) Will Use Its Cash Wisely